Impact of restricted access to, and low awareness of, mexiletine on people with myotonia: a real-world European survey

•MyoPath explores European patients’ views of the impact of mexiletine on myotonia.•Findings confirm the harm to myotonia patients if mexiletine access is limited.•Treatment was associated with fewer falls, less muscle stiffness, better mobility.•Treatment interruptions worsened myotonia and HRQoL.•MyoPath was a market research survey of clinicians, advocates, people with myotonia.